Evidence that Formulations of the Selective MAO-B Inhibitor, Selegiline, which Bypass First-Pass Metabolism, also Inhibit MAO-A in the Human Brain

Update on the pharmacology of selective inhibitors of MAO-A and MAO-B: Focus on modulation of CNS monoamine neurotransmitter release

(2014) John P.M. Finberg   PHARMACOLOGY & THERAPEUTICS

Current Place of Monoamine Oxidase Inhibitors in the Treatment of Depression

(2013) Kenneth I. Shulman et al.   CNS DRUGS

Distribution of Monoamine Oxidase Proteins in Human Brain: Implications for Brain Imaging Studies

(2013) Junchao Tong et al.   JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM

Drug Delivery in the Twenty-First Century: A New Paradigm

(2009) B Smith et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Effects of Modafinil on Dopamine and Dopamine Transporters in the Male Human Brain

(2009) Nora D. Volkow et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Reversible Inhibitors of Monoamine Oxidase-A (RIMAs): Robust, Reversible Inhibition of Human Brain MAO-A by CX157

(2009) Joanna S Fowler et al.   NEUROPSYCHOPHARMACOLOGY

Orally disintegrating selegiline for the treatment of Parkinson's disease

(2008) Matthias Löhle et al.   EXPERT OPINION ON PHARMACOTHERAPY

Quantitative Structure−Activity Relationship and Complex Network Approach to Monoamine Oxidase A and B Inhibitors

(2008) Lourdes Santana et al.   JOURNAL OF MEDICINAL CHEMISTRY

Brain Monoamine Oxidase A Activity Predicts Trait Aggression

(2008) N. Alia-Klein et al.   JOURNAL OF NEUROSCIENCE